SCHEMBL5576873

SCHEMBL5576873

CC(C)(C)Cn1c(C(=O)O)c(O)c2cc(Cl)c(Cl)cc2c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.36
KRAS P01116 1/20 0.36
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SRC P12931 3/20 0.34
PRKACA P17612 1/20 0.33
PRKACG P22612 1/20 0.33
PRKACB P22694 1/20 0.33
ABCB11 O95342 1/20 0.33
GRIA1 P42261 2/20 0.33
GRIA2 P42262 2/20 0.33
GRIA3 P42263 2/20 0.33
GRIA4 P48058 2/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5576492 0.85 MAPK8 (0.37) KRASPOLBGAANPSR1ALDH1A1
SCHEMBL5576576 0.80 PTGDR2 (0.41) DPP4PIK3CA
SCHEMBL5576489 0.80 EGLN1 (0.41) DPP4ALDH1A1
SCHEMBL5577145 0.80 PTGDR2 (0.43) DPP4PIK3CA
SCHEMBL5577125 0.77 CCR2 (0.33) DPP4KRASPOLBGAANPSR1
SCHEMBL5576633 0.76 CCR2 (0.41) DPP4ABCB11CCR2MEN1KMT2A
SCHEMBL5576501 0.75 GAA (0.36) POLBGAANPSR1MEN1KMT2A
SCHEMBL5577109 0.75 TNF (0.44) GAAMEN1KMT2AALDH1A1
Oxalic Acid SCHEMBL5576785 0.75 KDM4E (0.46) POLBGAAMEN1KMT2AALDH1A1
SCHEMBL5576892 0.74 PDE3B (0.39) POLBGAANPSR1ABCB11CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070117840-A1 Receptor antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 US disclosed
EP-1604983-A1 RECEPTOR ANTAGONIST Takeda Pharmaceutical Company Limited (JP) 2005-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117840-A1 Receptor antagonist FSHR, NR4A1, GHRHR DPP4 3633/4885KRAS 3424/4885POLB 3882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.